Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A large cell neuroendocrine carcinoma that involves the lung(s).
Biomarker and diagnostic research for pulmonary large cell neuroendocrine carcinoma has been reported in the published literature.
2 clinical trials registered. Interventions under study include drug therapy. Pipeline includes 2 PHASE1. Research is primarily industry-sponsored.
87 publications have been identified in PubMed for pulmonary large cell neuroendocrine carcinoma. Research spans Case Report / Case Series (32%), Review / Meta-Analysis (17%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 28 | 32% |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 8:34 PM UTC
Research summaries |
15 |
17% |
Laboratory research | 15 | 17% |
Testing and diagnosis research | 14 | 16% |
Disease patterns and progression | 9 | 10% |
Clinical study results | 3 | 3% |
New treatment approaches | 2 | 2% |
Other research | 1 | 1% |
Put A (2026). [PMID: 41854102](https://pubmed.ncbi.nlm.nih.gov/41854102/). *Cancer Rep (Hoboken)*. [Gene Therapy / Novel Therapeutics]
Merola E (2026). [PMID: 41899566](https://pubmed.ncbi.nlm.nih.gov/41899566/). *Cancers (Basel)*. [Review / Meta-Analysis]
Yücel H (2026). [PMID: 41598557](https://pubmed.ncbi.nlm.nih.gov/41598557/). *J Clin Med*. [Basic Science / Preclinical]
Yoh K (2026). [PMID: 42111278](https://pubmed.ncbi.nlm.nih.gov/42111278/). *Gynecol Oncol Rep*. [Case Report / Case Series]
Tashjian H (2026). [PMID: 41985228](https://pubmed.ncbi.nlm.nih.gov/41985228/). *Clin Lung Cancer*. [Case Report / Case Series]
Szpechcinski A (2026). [PMID: 41977128](https://pubmed.ncbi.nlm.nih.gov/41977128/). *Int J Mol Sci*. [Epidemiology / Natural History]
Hung YP (2026). [PMID: 41293870](https://pubmed.ncbi.nlm.nih.gov/41293870/). *Histopathology*. [Basic Science / Preclinical]
Murayama C (2026). [PMID: 42064973](https://pubmed.ncbi.nlm.nih.gov/42064973/). *Respir Med Case Rep*. [Case Report / Case Series]
Liu B (2026). [PMID: 41641108](https://pubmed.ncbi.nlm.nih.gov/41641108/). *Front Oncol*. [Case Report / Case Series]
Gujarathi R (2026). [PMID: 41968866](https://pubmed.ncbi.nlm.nih.gov/41968866/). *Cancer Med*. [Epidemiology / Natural History]
AI-curated news mentioning pulmonary large cell neuroendocrine carcinoma
Updated Jul 29, 2026
The FIRST-NEC GFPC 01-2022 trial protocol outlines an externally controlled trial to evaluate first-line immunochemotherapy for advanced large cell neuroendocrine lung carcinomas. This study aims to enhance treatment strategies for this rare cancer type.